Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.62 |
| ▸ | RARA | P10276 | 7/20 | 0.62 |
| ▸ | RARB | P10826 | 7/20 | 0.62 |
| ▸ | RARG | P13631 | 7/20 | 0.62 |
| ▸ | RXRB | P28702 | 3/20 | 0.62 |
| ▸ | RXRG | P48443 | 3/20 | 0.62 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.60 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538662 | 0.91 | RXRA (0.64) | RXRARARARARBRARGRXRB | |
| SCHEMBL6890777 | 0.88 | CYP2C9 (0.60) | RXRARARARARBRARGRXRB | |
| SCHEMBL727916 | 0.88 | RXRA (0.70) | RXRARARARARBRARGRXRB | |
| SCHEMBL6889482 | 0.87 | RXRA (0.58) | RXRARARARARBRARGRXRB | |
| SCHEMBL5537933 | 0.83 | RARA (0.60) | RXRARARARARBRARGRXRB | |
| SCHEMBL12181011 | 0.83 | RXRA (0.88) | RXRARARARARBRARGRXRB | |
| SCHEMBL1073921 | 0.82 | RXRA (0.76) | RXRARARARARBRARGRXRB | |
| SCHEMBL9446527 | 0.82 | CYP26A1 (0.80) | RXRARARARARBRARGRXRB | |
| SCHEMBL8461840 | 0.82 | CYP26A1 (0.80) | RXRARARARARBRARGRXRB | |
| SCHEMBL7721769 | 0.81 | RXRA (0.65) | RXRARARARARBRARGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2451455-A2 | RXR AGONIST COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5962731-A | MODIFY LIPID METABOLISM; SKIN DISORDERS,; AUTOIMMUNE DISEASES; FATTY ACID METABOLISM; ANTITUMOR AGENTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | NCOR1, NR4A2, NR4A3 | RXRA 4/4885RARA 38/4885RARB 37/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RARA 7/4885RARB 6/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RARA 18/4885RARB 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.